MoonLake Immunotherapeutics's Q2 net loss widens

MoonLake Immunotherapeutics

05/08/2025 12:15

Overview

MoonLake ends Q2 with $425.1 mln in cash, bolstered by $500 mln financing

R&D expenses rise to $49.8 mln, supporting clinical trial expansions

Phase 3 VELA program for HS on track, significant milestones expected

Outlook

Around September 2025: R&D Day to present top-line results for the HS Phase 3 VELA program

Q4 2025: Primary endpoint readout of the Phase 2 LEDA trial in PPP

Q1 2026: Primary endpoint readout of the Phase 2 S-OLARIS trial in axSpA

H1 2026: Primary endpoint readout of Phase 3 VELA-TEEN trial in adolescent HS

H1 2026: Primary endpoint readout of Phase 2 IZAR trial in PsA

Result Drivers

R&D EXPENSES - Increase driven by contract research and manufacturing costs, consulting expenses, and personnel-related costs for clinical trials

FINANCIAL POSITION - $500 mln non-dilutive financing agreement with Hercules Capital strengthens cash position and supports clinical objectives

CLINICAL TRIAL PROGRESS - Phase 3 VELA program in HS and Phase 2 LEDA trial in PPP progressing well, expected to drive future growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.87
Q2 Net Income
-$56.05 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for MoonLake Immunotherapeutics is $74.50, about 28.4% above its August 4 closing price of $53.32

Press Release: ID:nGNE6sBWth

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)